Tesamorelin is administered as a subcutaneous injection (under the skin), typically once a day. It works by acting as a growth hormone-releasing hormone (GHRH) analog, which stimulates the pituitary gland to release growth hormone, leading to a reduction in visceral fat.

Tirzepatide is administered as a weekly subcutaneous injection (under the skin). It acts as both a GLP-1 and GIP receptor agonist, which means it increases insulin release, reduces glucagon production, slows down stomach emptying, and enhances the feeling of fullness.